Predictive value of transabdominal ultrasound submucosal index combined with hs-CRP, IL-6 and IL-8 in the early treatment of ulcerative colitis patients

doi:10.3877/cma.j.issn.2095-2015.2025.01.011

Abstract

Abstract:

Objective

To explore the predictive value of transabdominal ultrasound submucosal index combined with highly sensitive C-reactive protein (hs-CRP), interleukin (IL)-6, and IL-8 in the early treatment of ulcerative colitis patients.

Methods

Patients with ulcerative colitis treated at the Emeishan People's Hospital from January 1, 2021 to December 31, 2022 were selected as the research objects. The treatment effect was evaluated early after treatment, and the patients were divided into a remission group and an unrelieved group based on the treatment effect. The transabdominal ultrasound results and clinical test indicators were compared between the two groups of patients, and the value of the transabdominal ultrasound combined with test indicators for predicting early treatment effect was evaluated.

Results

A total of 92 patients with ulcerative colitis were included in the study, of which 56 cases (60.87%) were in the remission group and 36 cases (39.13%) were in the unrelieved group. The differences in hs-CRP, IL-8,IL-6 between the remission group and the unrelieved group were statistically significant (P＜0.05).However, there were no statistically significant differences in body mass index, complications, erythrocyte sedimentation rate, white blood cell, hemoglobin, and ulcerative colitis endoscopic severity index (P＞0.05).The differences in submucosal thickness and submucosal index between the two groups were statistically significant (P＜0.05). In terms of intestinal wall thickness, there was no statistically significant difference between the two groups (P＞0.05). The above statistically significant factors were included in the binary multivariate logistic regression, and the results showed that hs-CRP, IL-8, IL-6, and submucosal index were the influencing factors for the early treatment effect of ulcerative colitis (P＜0.05). The ROC curve results showed that hs-CRP, IL-6, and submucosal index alone had a better predictive effect on early treatment of ulcerative colitis patients, with areas under the curve of 0.769, 0.772 and 0.779, respectively. However,IL-8 had a moderate predictive effect, with an area under the curve of 0.678. The accuracy of combining the submucosal index with hs-CRP, IL-8 and IL-6 in predicting early treatment outcomes in patients with ulcerative colitis was high (P＜0.05).

Conclusion

The combination of transabdominal ultrasound submucosal index and hs-CRP, IL-8 and IL-6 has high value in predicting early treatment outcomes in patients with ulcerative colitis.

Key words: Ulcerative colitis, Ultrasound, Highly sensitive C-reactive protein, Interleukin-6, Interleukin-8, Submucosal index

Wei Xue, Hua Zhu, Tao Jia. Predictive value of transabdominal ultrasound submucosal index combined with hs-CRP, IL-6 and IL-8 in the early treatment of ulcerative colitis patients[J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2025, 15(01): 55-59.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhxhbyyxzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-2015.2025.01.011

https://zhxhbyyxzz.cma-cmc.com.cn/EN/Y2025/V15/I01/55

Figures/Tables 6

组别	例数	性别[例(%)]		年龄[岁,M(P25,P75)]	民族[例(%)]
组别	例数	男	女	年龄[岁,M(P25,P75)]	汉族	其他民族
缓解组	56	30(53.57)	26(46.43)	41.00(38.50,43.00)	49(87.50)	7(12.50)
未缓解组	36	19(52.78)	17(47.22)	42.33(39.67,46.50)	31(86.11)	5(13.89)
统计值		0.006		-0.632	0.037
P值		0.941		0.529	0.847

组别	例数	体重指数(kg/m², $\overset{ˉ}{x}$ ±s)	并发症[例(%)]				红细胞沉降率(mm/1h, $\overset{ˉ}{x}$ ±s)	白细胞(10⁹/L, $\overset{ˉ}{x}$ ±s)
组别	例数	体重指数(kg/m², $\overset{ˉ}{x}$ ±s)	高血压	高脂血症	冠心病	糖尿病	红细胞沉降率(mm/1h, $\overset{ˉ}{x}$ ±s)	白细胞(10⁹/L, $\overset{ˉ}{x}$ ±s)
缓解组	56例	21.27±4.38	6(10.71)	1(1.79)	4(7.14)	7(12.50)	13.27±3.10	10.26±2.36
未缓解组	36例	21.79±4.11	8(22.22)	1(2.78)	2(5.56)	5(13.89)	14.38±3.48	9.95±2.17
统计值		-0.569	2.249	0.101	0.091	0.037	-1.597	0.634
P值		0.571	0.134	0.75	0.763	0.847	0.114	0.528
组别	例数	血红蛋白(g/L, $\overset{ˉ}{x}$ ±s)	hs-CRP(mg/L, $\overset{ˉ}{x}$ ±s)	IL-8(pg/mL, $\overset{ˉ}{x}$ ±s)	IL-6(pg/mL, $\overset{ˉ}{x}$ ±s)	UCEIS评分( $\overset{ˉ}{x}$ ±s)
缓解组	56例	97.79±15.48	14.79±3.27	65.38±8.27	204.38±56.37	4.12±0.57
未缓解组	36例	95.82±16.32	13.15±2.85	96.39±11.73	278.49±49.30	3.97±0.62
统计值		0.583	2.466	-14.87	-6.457	1.19
P值		0.561	0.016	＜0.001	＜0.001	0.237

组别	例数	体重指数(kg/m², $\overset{ˉ}{x}$ ±s)	并发症[例(%)]				红细胞沉降率(mm/1h, $\overset{ˉ}{x}$ ±s)	白细胞(10⁹/L, $\overset{ˉ}{x}$ ±s)
组别	例数	体重指数(kg/m², $\overset{ˉ}{x}$ ±s)	高血压	高脂血症	冠心病	糖尿病	红细胞沉降率(mm/1h, $\overset{ˉ}{x}$ ±s)	白细胞(10⁹/L, $\overset{ˉ}{x}$ ±s)
缓解组	56例	21.27±4.38	6(10.71)	1(1.79)	4(7.14)	7(12.50)	13.27±3.10	10.26±2.36
未缓解组	36例	21.79±4.11	8(22.22)	1(2.78)	2(5.56)	5(13.89)	14.38±3.48	9.95±2.17
统计值		-0.569	2.249	0.101	0.091	0.037	-1.597	0.634
P值		0.571	0.134	0.75	0.763	0.847	0.114	0.528
组别	例数	血红蛋白(g/L, $\overset{ˉ}{x}$ ±s)	hs-CRP(mg/L, $\overset{ˉ}{x}$ ±s)	IL-8(pg/mL, $\overset{ˉ}{x}$ ±s)	IL-6(pg/mL, $\overset{ˉ}{x}$ ±s)	UCEIS评分( $\overset{ˉ}{x}$ ±s)
缓解组	56例	97.79±15.48	14.79±3.27	65.38±8.27	204.38±56.37	4.12±0.57
未缓解组	36例	95.82±16.32	13.15±2.85	96.39±11.73	278.49±49.30	3.97±0.62
统计值		0.583	2.466	-14.87	-6.457	1.19
P值		0.561	0.016	＜0.001	＜0.001	0.237

指标	β	S.E	Wald	P	OR	95%CI
hs-CRP	1.482	0.466	3.251	0.001	4.392	1.802～10.726
IL-8	1.143	0.493	2.357	0.019	3.144	1.211～8.153
IL-6	1.003	0.451	2.196	0.029	2.718	1.116～6.603
黏膜下层厚度	0.874	0.483	1.816	0.705	2.394	0.933～6.162
黏膜下层指数	0.957	0.452	2.127	0.034	2.586	1.071～6.219

指标	曲线下面积	S.E	灵敏度(%)	特异性(%)	P	95%CI
hs-CRP	0.769	0.054	55.56	89.29	＜0.001	0.663～0.875
IL-8	0.678	0.055	77.78	58.93	0.004	0.570～0.784
IL-6	0.772	0.051	50.00	87.50	＜0.001	0.673～0.871
黏膜下层指数	0.779	0.051	63.89	87.50	＜0.001	0.678～0.880
指标联合	0.918	0.027	86.11	80.36	＜0.001	0.866～0.971

References 20

[1]	Le Berre C, Honap S, Peyrin-Biroulet L. Ulcerative colitis[J]. Lancet,2023, 402(10401): 571-584.
[2]	Vande Casteele N, Sandborn WJ, Feagan BG, et al. Real-world multicentre observational study including population pharmacokinetic modelling to evaluate the exposure-response relationship of vedolizumab in inflammatory bowel disease: ERELATE Study[J].Aliment Pharmacol Ther, 2022, 56(3): 463-476.
[3]	Sun Q, Tang Y, Dai L, et al. Serum Bile Acid Metabolites Predict the Therapeutic Effect of Mesalazine in Patients with Ulcerative Colitis[J]. J Proteome Res, 2023, 22(4): 1287-1297.
[4]	中华医学会消化病学分会炎症性肠病学组, 中国炎症性肠病诊疗质量控制评估中心. 中国溃疡性结肠炎诊治指南(2023年·西安)[J].中华炎性肠病杂志(中英文), 2024, 8(1): 33-58.
[5]	中华医学会消化病学分会炎症性肠病学组. 中国消化内镜技术诊断与治疗炎症性肠病的专家指导意见[J]. 中华炎性肠病杂志(中英文), 2020, 4(4): 283-291.
[6]	中华医学会消化病学分会炎症性肠病学组. 炎症性肠病外科治疗专家共识[J]. 中华炎性肠病杂志(中英文), 2020, 4(3): 180-199.
[7]	中华医学会消化病学分会炎症性肠病学组. 炎症性肠病诊断与治疗的共识意见(2018年·北京)[J]. 中国实用内科杂志, 2018, 38(9):796-813.
[8]	Gupta A, Yu A, Peyrin-Biroulet L, et al. Treat to Target: The Role of Histologic Healing in Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis[J]. Clin Gastroenterol Hepatol, 2021,19(9): 1800-1813.
[9]	Faye AS, Allin KH, Iversen AT, et al. Antibiotic use as a risk factor for inflammatory bowel disease across the ages: a population-based cohort study[J]. Gut, 2023, 72(4): 663-670.
[10]	Syal G, Robbins L, Kashani A, et al. Hypoalbuminemia and Bandemia Predict Failure of Infliximab Rescue Therapy in Acute Severe Ulcerative Colitis[J]. Dig Dis Sci, 2021, 66(1): 199-205.
[11]	Lei Y, Chen Y, Lin Z, et al. Comprehensive analysis of key biomarkers, immune infiltration and potential therapeutic agents for ulcerative colitis[J]. Life Sci, 2020, 260(1): 118437.
[12]	Kumar M, Murugesan S, Ibrahim N, et al. Predictive biomarkers for anti-TNF alpha therapy in IBD patients[J]. J Transl Med, 2024,22(1): 284.
[13]	段亚群. 血清IL-2, IL-6, IL-8, TNF-α, CRP在儿童IBD早期诊断及活动性评估中的应用研究[J]. 中国医学创新, 2023, 20(30): 5-9.
[14]	Wagatsuma K, Yokoyama Y, Nakase H. Role of Biomarkers in the Diagnosis and Treatment of Inflammatory Bowel Disease[J].Life(Basel), 2021, 11(12): 1375.
[15]	Tarapatzi G, Filidou E, Kandilogiannakis L, et al. Biomarkers in Inflammatory Bowel Diseases: Predicting the Indication and the Effect of Biologics[J]. J Gastrointestin Liver Dis, 2022, 31(2):229-243.
[16]	张龙, 唐艳云. 经腹超声黏膜下层指数对溃疡性结肠炎患者治疗反应性的预测价值[J]. 中国临床研究, 2023, 36(5): 689-692.
[17]	Yan BM, Sey MSL, Belletrutti P, et al. Reliability of the Endoscopic Ultrasound Ulcerative Colitis(EUS-UC) score for assessment of inflammation in patients with ulcerative colitis[J]. Endosc Int Open,2021, 9(7): E1116-E1122.
[18]	Bertani L, Baglietto L, Antonioli L, et al. Assessment of serum cytokines predicts clinical and endoscopic outcomes to vedolizumab in ulcerative colitis patients[J]. Br J Clin Pharmacol, 2020, 86(7):1296-1305.
[19]	Maaser C, Petersen F, Helwig U, et al. Intestinal ultrasound for monitoring therapeutic response in patients with ulcerative colitis:results from the TRUST&UC study[J]. Gut, 2020, 69(9): 1629-1636.
[20]	Sagami S, Kobayashi T, Aihara K, et al. Early improvement in bowel wall thickness on transperineal ultrasonography predicts treatment success in active ulcerative colitis[J]. Aliment Pharmacol Ther, 2022,55(10): 1320-1329.

Please choose a citation manager

Content to export